Stocks Health care BBNX
NASDAQ · Health careBeta Bionics, Inc. (BBNX)
Beta Bionics, Inc. brought in $127.3M of revenue over the twelve months to September 30, 2026, up 43.7% from a year earlier. It posted a net loss of $83.1M. In fiscal 2025 capital spending exceeded operating cash flow by $56.2M. At September 30, 2026 it held $81.6M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on October 27, 2026.
Key facts about Beta Bionics, Inc.
- Net worth
- Beta Bionics, Inc. has a market value (market cap) of $762.6M at the latest share price, and shareholders' equity of $401.4M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $100.3M (+53.9% year on year), with a net loss of $73.2M. Over the 12 months to September 30, 2026: revenue $127.3M, net loss $83.1M.
- Cash flow
- In fiscal 2025 operations used $50.9M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on October 27, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Beta Bionics, Inc.'s next report is expected around January 7, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Beta Bionics, Inc. does
Beta Bionics, Inc. is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NASDAQ under the ticker BBNX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $100.3M | -$73.2M | -$1.81 | -$56.2M |
| 2024 | $65.1M | -$54.8M | -$8.60 | -$51.7M |
| 2024 | $12M | -$44.1M | -$8.31 | -$32.8M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where BBNX ranks in Health care
Latest SEC filings
What Beta Bionics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026Passive stake changed SCHEDULE 13G/A
- October 27, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 30% to $35.5M versus the same quarter last year; diluted EPS -$0.52 versus -$0.33.
- October 27, 2026
- October 7, 2026Passive stake (5% or more) SCHEDULE 13G
- September 17, 2026Other event 8-K
- September 15, 2026
- August 13, 2026Passive stake changed SCHEDULE 13G/A
- July 29, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 38% to $32M versus the same quarter last year; diluted EPS -$0.53 versus -$0.39.
- July 29, 2026
- July 24, 2026Passive stake (5% or more) SCHEDULE 13G
Insider trades
What the people running Beta Bionics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $2.4M worth of shares in the last 90 days and bought none on the open market. Most of the selling (71%) was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 5, 2026 | Feider StephenChief Financial Officer | Exercised options | 382 | $1.9K |
| November 5, 2026 | Feider StephenChief Financial Officer | Soldpre-planned (10b5-1) | 382 | $6.5K |
| November 2, 2026 | Hopman MarkChief Commercial Officer | Soldpre-planned (10b5-1) | 370 | $6.3K |
| October 27, 2026 | Mensinger MikeChief Product Officer | Soldpre-planned (10b5-1) | 2,650 | $58.3K |
| October 26, 2026 | Hopman MarkChief Commercial Officer | Soldpre-planned (10b5-1) | 821 | $16.4K |
| October 14, 2026 | Hopman MarkChief Commercial Officer | Soldpre-planned (10b5-1) | 775 | $13.4K |
| October 1, 2026 | Hopman MarkChief Commercial Officer | Soldpre-planned (10b5-1) | 370 | $7K |
| September 22, 2026 | Jones ChristyDirector | Soldpre-planned (10b5-1) | 6,430 | $147.9K |
Who owns BBNX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| T. Rowe Price Associates, Inc.13G, passive | 16.6% | October 7, 2026 |
| Eventide Asset Management, LLC13G, passive with 2 related filers | 13.4% | May 15, 2026 |
| Levy Guy13G, passive with 8 related filers | 8.7% | November 9, 2026 |
| Sands Capital Life Sciences Pulse Fund II. L.P.13G, passive with 2 related filers | 8.2% | August 13, 2025 |
| Dapice Joshua J.13G, passive with 27 related filers | 8.1% | May 12, 2026 |
| Divisadero Street Capital Management, LP13G, passive with 4 related filers | 6.9% | July 24, 2026 |
| Guy Levy13G, passive with 12 related filers | 5.8% | February 12, 2026 |
| Point72 Asset Management, L.P.13G, passive with 2 related filers | 5.2% | February 23, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 134 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Eventide Asset Management, LLC | 6,253,673 | +308,185 |
| Soleus Capital Management, L.P. | 4,393,714 | +39,213 |
| Morgan Stanley | 4,266,822 | +39,188 |
| Sands Capital Alternatives, LLC | 3,708,043 | 0 |
| BlackRock, Inc. | 3,340,171 | +301,576 |
| Point72 Asset Management, L.P. | 2,254,683 | -270,357 |
| Vanguard Capital Management LLC | 1,782,346 | +54,369 |
| Vestal Point Capital, LP | 1,600,000 | -611,518 |
| Rtw Investments, LP | 1,500,000 | -500,000 |
| Deerfield Management Company, L.P. | 1,324,000 | 0 |
| Omega Fund Management, LLC | 1,316,183 | 0 |
| Eversept Partners, LP | 1,249,441 | -165,397 |
| Divisadero Street Capital Management, LP | 1,113,802 | new |
| Geode Capital Management, LLC | 1,073,452 | +140,774 |
| State Street Corp | 970,192 | +24,105 |
| Millennium Management LLC | 956,244 | +95,378 |
| Balyasny Asset Management L.P. | 855,682 | +237,767 |
| Perceptive Advisors LLC | 832,944 | -10,000 |
| Jpmorgan Chase & Co | 703,356 | +396,127 |
| Bruce & Co., Inc. | 665,700 | +115,000 |
Insiders
11 insiders reported holding 1,159,002 shares in total, about $19.6M at the last price.
| Holder | Shares |
|---|---|
| Saint SeanPresident & CEO, Director | 398,429 |
| Mensinger MikeChief Product Officer | 174,740 |
| Russell Steven JonChief Medical Officer | 169,628 |
| Feider StephenChief Financial Officer | 159,378 |
| Lezack AdamDirector | 55,796 |
| Hopman MarkChief Commercial Officer | 54,143 |
| Michel Gerard JDirector | 33,509 |
| Dearen Danny L.Director | 32,209 |
| Carney SeanDirector | 32,209 |
| Palasis MariaDirector | 29,397 |
Questions about BBNX
What does Beta Bionics, Inc. do?
Beta Bionics, Inc. is a company in the Health care sector, listed on NASDAQ as BBNX. Its shares trade on NASDAQ under the ticker BBNX.
What is Beta Bionics, Inc.'s net worth?
Beta Bionics, Inc. has a market value (market cap) of $762.6M at the latest share price, and shareholders' equity of $401.4M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Beta Bionics, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $83.1M on revenue of $127.3M.
How much revenue does Beta Bionics, Inc. make?
Over the twelve months to September 30, 2026 Beta Bionics, Inc. reported revenue of $127.3M. That is 43.7% more than a year earlier.
When did Beta Bionics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on October 27, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the passive stake changed from November 9, 2026.
When is Beta Bionics, Inc.'s next earnings report?
Beta Bionics, Inc.'s next report is expected around January 7, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare BBNX with
Follow BBNX
Get an email when Beta Bionics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Beta Bionics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.